Neuraxis, Inc. earnings releases NRXS

Annual Quarterly

Neuraxis, Inc. last reported quarterly results on Apr 21, 2026, for Q1 FY2026 (the quarter ended Mar 31, 2026): revenue of $1.6 million (+79.5% year over year) and diluted EPS of -$0.18. It usually reports 8–43 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Apr 21, 2026 21 days after quarter end	Q1 FY2026 ended Mar 31, 2026	2 +79.5%	-2 +22.7%	-0.18 +45.5%
Oct 23, 2025 23 days after quarter end	Q3 FY2025 ended Sep 30, 2025	1 +21.7%	-2 -20.9%	-0.24 +4.0%
Jan 8, 2025 8 days after quarter end	Q4 FY2024 ended Dec 31, 2024	1 +43.2%	-1 +9.1%	-0.22 +25.8%
Nov 12, 2024 43 days after quarter end	Q3 FY2024 ended Sep 30, 2024	1 +39.6%	-2 +79.7%	-0.25 +89.5%
Aug 9, 2024 40 days after quarter end	— ended Jun 30, 2024	—	—	—
Apr 9, 2024 9 days after quarter end	— ended Mar 31, 2024	—	—	—

Company profile

Industry: Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as: NRXS (NYSE)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Carmel, IN
SEC filer status: , Emerging growth company
SEC CIK: 1933567

Other Electromedical & Electrotherapeutic Apparatus companies

All 31 Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.